title-bar

Valuation of Torrent Pharma attractive: Nomura

By: |
Published: February 6, 2016 12:05:55 AM

India domestic formulations market registered a moderate y-o-y growth of 7%. The discontinuation of product schemes/bonus in the domestic business led to the slowdown.

India domestic formulations market registered a moderate y-o-y growth of 7%. The discontinuation of product schemes/bonus in the domestic business led to the slowdown. We present the bonus % trend for TRP. Management expects growth to pick up 4QFY16 onwards. TRP’s YTD growth in India is 14%.

The sales force was rationalized by 300 representatives in 3QFY16 on account of the merger of select divisions. As a result, the MR (medical representative) productivity improved 31% y-o-y.The company launched Adalimumab in 3QFY16 at one fifth the price of the innovator. TRP’s existing relationship with rheumatologists will likely aid in prescription generation for the product. We maintain a positive outlook towards TRP’s domestic business and have built in growth of 16%/18% during FY16F/FY17F in our estimates.

The stock trades at 21.4x FY17F and 17.5x FY18F base EPS (EPS ex non-sustainable US opportunities) of Rs 63.2 and 77.4, respectively. We find the valuation attractive given the strong domestic business and a strong balance sheet.

Get live Stock Prices from BSE and NSE and latest NAV, portfolio of Mutual Funds, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Switch to Hindi Edition